Topamax (topiramate) Tablets/Sprinkle Capsules - Dec 30, 2003
December 30, 2003
Audience: Neurologists and other Healthcare professionals
Ortho-McNeil and FDA revised the WARNINGS and PRECAUTIONS sections of the prescribing information, notifying healthcare professionals that Topamax causes hyperchloremic, non-anion gap metabolic acidosis (decreased serumbicarbonate). Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended.
[December 2003
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.